본문으로 건너뛰기
← 뒤로

[Rheumatology : what's new in 2022].

Revue medicale suisse 2023 Vol.19(812) p. 239-242

Iudici M, Lazarou I, Nissen MJ, Lauper K

관련 도메인

📝 환자 설명용 한 줄

In rheumatology, this year has seen an expansion of knowledge about the treatment of rheumatoid arthritis, with the availability of results from randomized trials evaluating a new molecule targeting I

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Iudici M, Lazarou I, et al. (2023). [Rheumatology : what's new in 2022].. Revue medicale suisse, 19(812), 239-242. https://doi.org/10.53738/REVMED.2023.19.812.239
MLA Iudici M, et al.. "[Rheumatology : what's new in 2022].." Revue medicale suisse, vol. 19, no. 812, 2023, pp. 239-242.
PMID 36723656

Abstract

In rheumatology, this year has seen an expansion of knowledge about the treatment of rheumatoid arthritis, with the availability of results from randomized trials evaluating a new molecule targeting IL-6, and regarding the safety profile of tofacitinib compared to TNF-alpha inhibitors. Interesting data on the outcome of pregnancy in patients with spondylarthritis have also been published. New molecules and different treatment strategies have shown promising results in psoriatic arthritis and systemic lupus erythematosus. The utility of botulinum toxin A injections for Raynaud's phenomenon and the efficacy of transplantation of autologous adipose-derived regenerative cells for the treatment of hand dysfunctions have been questioned by 2 randomized controlled trials of patients with systemic sclerosis.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 1

MeSH Terms

Humans; Rheumatology; Botulinum Toxins, Type A; Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Scleroderma, Systemic

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문